Crain's Chicago Business
From M&A to drug prices to regulatory shifts: here’s what to expect in 2025 in the life sciences sector
The life sciences sector is in constant flux, facing regulatory changes, shifting political and technological landscapes and the acceleration of digital transformation. Baker Tilly’s 2025 Life Sciences Industry Forecast is a must-read for executives, investors and others in this critical sector.
|
•
|
Capital markets trends: IPOs and M&A in life sciences was up in 2024. Learn why valuations and funding will continue to accelerate in 2025.
|
•
|
The challenges of rising drug prices: The rise in pharmacy benefit managers, spread pricing and rebate retention drive calls for pricing transparency. Here’s why it matters.
|
•
|
Technology’s compliance impact: Technology is changing the way life sciences companies engage with health care professionals and ensure compliance.
|
•
|
Evidence generation: Too few early-stage companies prioritize evidence generation planning. Learn how such planning can improve market access and commercialization.
|
Download the 2025 Life Sciences Industry Forecast from Baker Tilly for more insights on the challenges and opportunities facing the life sciences sector this year.
|
Baker Tilly Advisory Group, LP and Baker Tilly US, LLP, trading as Baker Tilly, are members of the global network of Baker Tilly International Ltd., the members of which are separate and independent legal entities. Baker Tilly US, LLP is a licensed CPA firm that provides assurance services to its clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and consulting services to their clients and are not licensed CPA firms. © 2025 Baker Tilly Advisory Group, LP The information provided here is of a general nature and is not intended to address the specific circumstances of any individual or entity. In specific circumstances, the services of a professional should be sought.
|
Connect with Crain's Chicago Business
|
|
|
|
|
|